Table 4.
Clinical Characteristics of HIV-Infected Transgender Women, According to Age—Transcendendo Cohort, Rio de Janeiro, Brazil, 2015–2017
| Clinical characteristics | Total N=174 (%) | 18–24 N=30 (%) | 25–35 N=69 (%) | 36–45 N=44 (%) | 46+N=31 (%) | p |
|---|---|---|---|---|---|---|
| Mode of HIV acquisition | ||||||
| Sex with men | 161 (92.5) | 27 (90.0) | 66 (95.7) | 43 (97.7) | 25 (80.6) | 0.042 |
| IDU | 2 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (6.5) | |
| Other/unknown | 11 (6.5) | 3 (10.0) | 3 (4.3) | 1 (2.3) | 4 (12.9) | |
| Current CD4 count (cells/mm3)a | ||||||
| <250 | 21 (12.1) | 2 (6.7) | 11 (15.9) | 4 (9.1) | 4 (12.9) | 0.884 |
| 251–500 | 36 (20.7) | 6 (20.0) | 15 (21.7) | 9 (20.5) | 6 (19.4) | |
| >500 | 84 (48.3) | 16 (53.3) | 29 (42.0) | 25 (56.8) | 14 (45.2) | |
| Missing | 33 (19.0) | 6 (20.0) | 14 (20.3) | 6 (13.6) | 7 (22.6) | |
| Currently on ART | ||||||
| No | 70 (40.2) | 25 (83.3) | 36 (52.2) | 6 (13.6) | 3 (9.7) | <0.001 |
| Yes | 104 (59.8) | 5 (16.7) | 33 (47.8) | 38 (86.4) | 28 (90.3) | |
| Current HIV RNA viral load (copies/mL) (N=103)b | ||||||
| <40 | 70 (67.3) | 4 (80.0) | 23 (69.7) | 27 (71.1) | 16 (57.1) | 0.775 |
| ≥40 | 22 (21.2) | 1 (20.0) | 5 (15.2) | 8 (21.1) | 8 (28.6) | |
| Missing | 12 (11.5) | 0 (0.0) | 5 (15.2) | 3 (7.9) | 4 (14.3) | |
| Had previous AIDS-defining illness | 40 (23.0) | 2 (6.7) | 8 (11.6) | 17 (38.6) | 13 (41.9) | <0.001 |
| Had previous TBc | 29 (16.7) | 2 (6.7) | 11 (15.9) | 11 (25.0) | 10 (32.3) | 0.051 |
a
Continuous variables were reclassified as categorical.
b
Calculated only for those on ART.
c
After HIV diagnosis.
ART, antiretroviral therapy; IDU, injection drug use.